Objective: To observe the changes and clinical significance of serum lysyl oxidase-like protein 2 (LOXL2), transforming growth factor-β (TGF-β) and connective tissue growth factor (CTGF) in patients with connective tissue disease and interstitial lung disease (CTD-ILD) before and after treatment with cyclophosphamide.Methods: From March 2021 to May 2022, 30 patients with CTD-ILD who were admitted to the Department of Rheumatology and Immunology, the First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology and treated with intravenous infusion of cyclophosphamide were selected. The clinical data, imaging data and laboratory data of patients at baseline before treatment and 12 weeks and 24 weeks after treatment with cyclophosphamide were observed. The changes and clinical significance of serum LOXL2, TGF-β and CTGF in patients with CTD-ILD before and after treatment with cyclophosphamide were analyzed. Results: After 24 weeks of treatment with cyclophosphamide, the levels of serum ESR, IgM, IgA and IgG in patients with CTD-ILD were significantly decreased, and the lung function indexes TLC, FVC, FEV1/FVC and DLCO% were significantly improved (P＜0.05). After 12 weeks and 24 weeks of treatment, the levels of serum LOXL2, TGF-β and CTGF were significantly decreased, and 6-MWT was significantly improved. HRCT score and CRP score were significantly lower (P＜0.05). There was no significant difference in C-reactive protein and blood gas analysis indexes PaO2 and PaCO2 after 12 weeks and 24 weeks of treatment (P＞0.05). The level of serum LOXL2 in CTD-ILD patients was positively correlated with ESR, IgA and IgG (P＜0.05). LOXL2 was positively correlated with TGF-β and CTGF (P=0.001, 0.003), TGF-β was positively correlated with CTGF (P=0.025). Conclusion: Cyclophosphamide may inhibit TGF-β signaling pathway by inhibiting the expression of serum LOXL2, and then affect the expression of CTGF to effectively control pulmonary fibrosis in patients with CTD-ILD.
HAN Feng
,
WANG Yongfu
,
LU Fuai
. The changes and clinical significance of LOXL2, TGF-β and CTGF in patients with connective tissue disease associated with interstitial lung disease before and after treatment with cyclophosphamide[J]. Journal of Baotou Medical College, 2024
, 40(5)
: 48
-54
.
DOI: 10.16833/j.cnki.jbmc.2024.05.010
[1] Saketkoo LA, Matteson EL, Brown KK, et al. Developing disease activity and response criteria in connective tissue disease-related interstitial lung disease[J]. J Rheumatol, 2011, 38(7): 1514-1518.
[2] 黄莎, 耑冰, 赵霞, 等. 结缔组织病相关间质性肺病临床特征分析[J]. 世界最新医学信息文摘, 2020, 20(26): 52.
[3] Van Den Bosch L, Luppi F, Ferrara G, et al. Immunomodulatory treatment of interstitial lung disease[J]. Ther Adv Respir Dis, 2022, 16: 17534666221117002.
[4] Watters LC, King TE, Schwarz MI, et al. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis[J]. Am Rev Respir Dis, 1986, 133(1): 97-103.
[5] Müller NL, Mawson JB, Mathieson JR, et al. Sarcoidosis: correlation of extent of disease at CT with clinical, functional, and radiographic findings[J]. Radiology, 1989, 171(3): 613-618.
[6] Wang YL, Li LR. Rituximab for connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis[J]. Int J Rheum Dis, 2023, 26(2): 225-235.
[7] 李丽敏. 长期霉酚酸酯与环磷酰胺治疗间质性肺病的转归及耐受观察[J]. 临床肺科杂志, 2018, 23(4): 739-741.
[8] Lucero HA, Kagan HM. Lysyl oxidase: an oxidative enzyme and effector of cell function[J]. Cell Mol Life Sci, 2006, 63(19/20): 2304-2316.
[9] Kagan H M, Li W D. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell[J]. J Cell Biochem, 2003, 88(4): 660-672.
[10] Magdaleno F, Trebicka J. Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression[J]. Gut, 2017, 66(9): 1540-1541.
[11] Millanes-Romero A, Herranz N, Perrera V, et al. Regulation of heterochromatin transcription by Snail1/LOXL2 during epithelial-to-mesenchymal transition[J]. Mol Cell, 2013, 52(5): 746-757.
[12] Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment[J]. Nat Med, 2010, 16(9): 1009-1017.
[13] Aumiller V, Strobel B, Romeike M, et al. Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis[J]. Sci Rep, 2017, 7(1): 149.
[14] Wen XH, Liu Y, Bai Y, et al. LOXL2, a copper-dependent monoamine oxidase, activates lung fibroblasts through the TGF-β/Smad pathway[J]. Int J Mol Med, 2018, 42(6): 3530-3541.
[15] 白羽, 郑毅. 赖氨酰氧化酶样蛋白-2在肺纤维化小鼠中的表达及意义[J]. 中华风湿病学杂志,2015, 19(9): 606-610, 后插1.
